Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$103.80
+0.8%
$103.45
$71.88
$107.53
$153.56B0.687.67 million shs7.22 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$85.46
+0.7%
$84.01
$57.52
$117.19
$33.51B1.444.41 million shs3.67 million shs
ResMed Inc. stock logo
RMD
ResMed
$258.09
+0.8%
$249.64
$195.00
$263.05
$37.84B0.77982,448 shs637,776 shs
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$229.27
+1.4%
$216.38
$187.43
$352.33
$16.47B1.09867,538 shs669,898 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boston Scientific Corporation stock logo
BSX
Boston Scientific
+0.51%-0.59%+2.91%+11.48%+34.57%
DexCom, Inc. stock logo
DXCM
DexCom
+1.33%+1.54%-0.95%+26.11%-23.43%
ResMed Inc. stock logo
RMD
ResMed
-0.37%-0.09%+1.88%+21.57%+34.36%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
+2.49%+2.19%+1.03%+10.91%-29.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Boston Scientific Corporation stock logo
BSX
Boston Scientific
4.6473 of 5 stars
3.63.00.04.23.12.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.8727 of 5 stars
3.55.00.04.72.42.51.9
ResMed Inc. stock logo
RMD
ResMed
4.665 of 5 stars
2.33.03.34.64.01.71.3
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
4.7462 of 5 stars
3.44.01.73.22.51.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boston Scientific Corporation stock logo
BSX
Boston Scientific
3.13
Buy$116.0911.84% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5015.26% Upside
ResMed Inc. stock logo
RMD
ResMed
2.64
Moderate Buy$259.330.48% Upside
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
2.89
Moderate Buy$320.0039.57% Upside

Current Analyst Ratings Breakdown

Latest BSX, DXCM, RMD, and WST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$245.00
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$118.00
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/28/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00
5/22/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/22/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$119.00 ➝ $125.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/20/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$286.00
5/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$120.00 ➝ $125.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$16.75B9.17$3.70 per share28.06$14.93 per share6.95
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B8.31$2.29 per share37.27$5.38 per share15.88
ResMed Inc. stock logo
RMD
ResMed
$4.69B8.08$9.28 per share27.81$33.11 per share7.80
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$2.90B5.69$9.37 per share24.47$37.04 per share6.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$1.85B$1.3775.7632.132.6611.58%18.67%10.38%7/23/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3463.7834.741.7912.90%30.05%10.00%7/30/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9128.9724.911.6126.15%25.67%18.59%7/31/2025 (Estimated)
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$492.70M$6.3735.9929.175.4216.13%18.23%13.51%7/24/2025 (Estimated)

Latest BSX, DXCM, RMD, and WST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q4 2025
ResMed Inc. stock logo
RMD
ResMed
$2.47N/AN/AN/A$1.33 billionN/A
7/30/2025Q2 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.45N/AN/AN/A$1.13 billionN/A
7/24/2025Q2 2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.51N/AN/AN/A$725.11 millionN/A
7/23/2025Q2 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.72N/AN/AN/A$4.89 billionN/A
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/24/2025Q1 2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.22$1.45+$0.23$1.23$685.24 million$698.00 million
4/23/2025Q1 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.36$2.37+$0.01$2.48$1.28 billion$1.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.82%N/A23.79%13 Years
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$0.840.37%N/A13.19%N/A

Latest BSX, DXCM, RMD, and WST Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
quarterly$0.210.39%7/30/20257/30/20258/6/2025
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.47
1.45
0.88
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
ResMed Inc. stock logo
RMD
ResMed
0.12
3.41
2.49
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.08
2.77
2.03

Institutional Ownership

CompanyInstitutional Ownership
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
ResMed Inc. stock logo
RMD
ResMed
54.98%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
93.90%

Insider Ownership

CompanyInsider Ownership
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
ResMed Inc. stock logo
RMD
ResMed
0.71%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
53,0001.48 billion1.47 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
9,980146.63 million145.59 millionOptionable
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
10,60071.85 million71.46 millionOptionable

Recent News About These Companies

West to Host Second-Quarter 2025 Conference Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$103.80 +0.84 (+0.81%)
Closing price 03:59 PM Eastern
Extended Trading
$104.12 +0.33 (+0.32%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$85.46 +0.59 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$84.99 -0.47 (-0.55%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

ResMed stock logo

ResMed NYSE:RMD

$258.09 +2.11 (+0.83%)
Closing price 03:59 PM Eastern
Extended Trading
$252.02 -6.08 (-2.36%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

West Pharmaceutical Services stock logo

West Pharmaceutical Services NYSE:WST

$229.27 +3.09 (+1.37%)
Closing price 03:59 PM Eastern
Extended Trading
$229.32 +0.04 (+0.02%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.